Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Johnson & Johnson: Strengths, Weaknesses, Opportunities, Threats

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Today, I'd like to focus on Johnson & Johnson (NYSE: JNJ  ) , the 124-year-old behemoth that sells everything from baby shampoo to Splenda to stents. It's been in the news recently with recalls of many medicines, but this giant will probably be around for another century.


  • Broad diversity of products. Not reliant on a sole product line for majority of revenue.
  • Repeat customers. People tend to be brand-loyal. If they buy Tylenol for their headaches, they tend to repeatedly buy Tylenol.
  • Strong brands. "No more tears" shampoo, Band-Aid, Tylenol, Visine, etc.
  • Generally smart purchasing of companies. For instance, it didn't purchase Guidant after Boston Scientific (NYSE: BSX  ) had bid the price up beyond what J&J was willing to pay.


  • A conglomerate of relatively independent companies. Sometimes they can go off the reservation, such as what appears to have happened with McNeil Consumer Healthcare and the making of the children's medicine now being recalled.
  • Several of its big drugs have lost or will soon lose patent protection.
  • Many of its products are commodities. For instance, other adhesive bandages exist, not just Band-Aid.


  • Development of personalized drugs that work best on specific genetic profiles, such as Gleevec from Novartis (NYSE: NVS  ) , which works well against specific mutations in people with chronic myeloid leukemia.
  • Continued smart purchasing of companies with complementary products.


  • Increasing pressure to move to generic drugs.
  • Stiff competition in stents, especially from Abbott Labs (NYSE: ABT  ) , Boston Scientific, and Medtronic (NYSE: MDT  ) , and having to keep one step ahead of everyone else.

What parts of J&J's SWOT need more detail? Fill in the blanks by using the comments section below.

Fool editor Jim Mueller owns shares of J&J but of no other company mentioned. Novartis is a Motley Fool Global Gains pick. Johnson & Johnson is an Income Investor recommendation, and Motley Fool Options has recommended buying calls on its stock. The Fool owns shares of Medtronic. The Fool's disclosure policy sweats SWOT at every opportunity.

Read/Post Comments (0) | Recommend This Article (13)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1202964, ~/Articles/ArticleHandler.aspx, 10/1/2016 8:46:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
JNJ $118.13 Up +0.86 +0.73%
Johnson and Johnso… CAPS Rating: *****
ABT $42.29 Up +0.85 +2.05%
Abbott Laboratorie… CAPS Rating: *****
BSX $23.80 Up +0.50 +2.15%
Boston Scientific CAPS Rating: ***
MDT $86.40 Up +1.00 +1.17%
Medtronic CAPS Rating: *****
NVS $78.96 Down -0.29 -0.37%
Novartis CAPS Rating: ****